Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2016 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results

EMERYVILLE, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
June 07, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome

EMERYVILLE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders,...
May 05, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine...
January 19, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...